MBOT is the ticker symbol for Microbot Medical Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks MBOT with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is MBOT a good stock to buy?

MBOT is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/MBOT.

Where does 13F Pro source MBOT data?

All Microbot Medical Inc. fundamentals and ownership data come directly from SEC EDGAR. Microbot Medical Inc. files with the SEC under CIK 883975. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Microbot Medical Inc.(MBOT)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Microbot Medical Inc. (MBOT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. MBOT is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.4m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Microbot Medical Inc. reports quarterly revenue of $241.0K, net income of $-5.6M, free cash flow of $-5.1M. Top institutional holders of MBOT by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, Mitsubishi UFJ Asset Management , Ltd., BlackRock, based on the most recent SEC filings. MBOT trades on the Nasdaq exchange and files with the SEC under CIK 883975. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Microbot Medical Inc. directly from SEC EDGAR.

Revenue

$241.0K

Net Income

$-5.6M

Free Cash Flow

$-5.1M

MBOT key financials by period

Microbot Medical Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2015	10-K	$116.9K	$-921.0K	—
FY 2013	10-K	$172.3K	$-26.4M	—
FY 2012	10-K	$1.4M	$-28.5M	—
FY 2011	10-K	$1.2M	$-21.3M	—
FY 2010	10-K	$1.4M	$-25.2M	—
FY 2009	10-K	$992.9K	$-27.0M	—

Institutions holding MBOT

Institutional investors reporting a position in Microbot Medical Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
VANGUARD CAPITAL MANAGEMENT	2,906,810	$5.7M	2026-06-30
Mitsubishi UFJ Asset Management , Ltd.	1,268,453	$2.5M	2026-06-30
BlackRock	902,411	$1.8M	2026-06-30
GEODE CAPITAL MANAGEMENT	836,271	$1.6M	2026-06-30
UBS Group AG	806,847	$1.6M	2026-06-30
DnB Asset Management AS	677,498	$1.3M	2026-06-30
STIFEL FINANCIAL	589,924	$1.2M	2026-06-30
MARSHALL WACE, LLP	541,963	$1.1M	2026-06-30
SUSQUEHANNA INTERNATIONAL GROUP, LLP	525,827	$1.0M	2026-06-30
VANGUARD FIDUCIARY	431,033	$840.5K	2026-06-30

SEC EDGAR: CIK 883975 →

Microbot Medical Inc.

MBOT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.4M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.